<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">


Press Releases

Our latest announcements

Biodesix Announces New VeriStrat® Data to be Presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium

A retrospective analysis of serum samples from the phase III study, EGF30008, will be presented at the 34th Annual San Antonio Breast Cancer Symposium SABCS.

Lung Cancer Study Evaluating Changes in VeriStrat Status over the Course of Treatment with Gefitinib Published in Journal of Thoracic Oncology

Publication announced today: Changes in plasma mass-spectral (VeriStrat) profile in course of treatment of NSCLC patients with EGFR-TKIs.

Biodesix to Present at BioConference Live – Innovative Online Conference

BioConference Live has selected Biodesix to present at the 5th annual Life Sciences conference, taking place online on October 26–27.

VeriStrat® Results Correlate with Survival Outcomes in Kidney Cancer Patients

Data show that VeriStrat was able to stratify renal cell carcinoma (RCC) patients treated with a combination of two targeted therapies.

Biodesix to Work with Concentra and Hooper Holmes to Expand Access to VeriStrat®

The initiation of two strategic partnerships that will provide cancer patients greater and more convenient options for completing VeriStrat testing.

Biodesix Selected to Present at Multi-State Investor and Partnering Conference

Biodesix is one of 30 companies chosen to present at the regional conference held biennially by the Colorado BioScience Association (CBSA).

Biodesix Closes Series D Financing - July 2011

Biodesix has closed a $20 million series D financing. The new capital will support ongoing commercialization activities for the company's Veristrat.

Biodesix Supports Unique Lung Cancer Research Initiative – CASTLE study enrolls initial subjects

Biodesix announces the enrollment of initial subjects into CASTLE, the inaugural study of the Addario Lung Cancer Medical Institute.

Biodesix Issued Four Additional U.S. Patents for Blood-based Oncology Tests

Biodesix announced that the U.S. Patent & Trademark Office has issued four patents for the protection of the company's products and technology.

Biodesix Receives Certification from NY State

Biodesix has received the clinical laboratory evaluation program certification from the New York State Department of Health’s Wadsworth Center.